Not in Madrid: Unlike the Tour de France, which finishes with the peloton procession in Paris today, we’re not yet at the ESMO20 finish line and there’s plenty of the data at Congress yet to come.
As you can see, we’re hoping ESMO21 will actually take place in Paris next year, but it’s definitely too early to make travel plans the way COVID-19 infection rates are increasing in Europe.
If we think of cancer drugs as like macarons that come in many versions – which ones do you like at #ESMO20 so far? There are are also subtle gradations in colour and flavour, reflective of a few trial differences to consider.
In this latest post we’re continuing our coverage of highlights from Saturday at ESMO20 with the second part of our commentary and analysis around some of the oral presentations involving numerous solid tumours, excluding breast cancer (see separate highlights of the day post), which caught our attention.
To learn more from our oncology analysis and obtain insights and commentary around data being presented at ESMO20, subscribers can log-in or you can click to gain access to BSB Premium Content.
We’ll have “boots on the ground” for the 2018 Congress of the European Society for Medical Oncology (Twitter: #ESMO18) that starts out of the gate on Friday in Munich.
The Fall cancer conference season is in swing…
Our conference coverage is not only about what data we think matters, particularly in the fast-moving world of immuno-oncology, but more importantly, why it matters.
Next up in our ESMO18 Previews, we take a closer look at renal cancer, an area that received some attention in Madrid last year and is likely to receive renewed focus again.
We also include a look at the broader RCC landscape in terms of US physician prescribing habits (i.e. KOL and Community oncologists), including some trend data to explore the impact of the nivo/ipi combination and cabozantinib data, as well as excerpts from an expert interview we conducted with Dr Awny Farajallah, Head of U.S. Medical at Bristol Myers Squibb.
Finally, we also highlight some key abstracts to watch out for in renal cell carcinoma (RCC) that are expected to be presented at ESMO18 and explore their relevance.
To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.